Italia markets closed

Dow Jones
39.989,02
-14,57(-0,04%)
Nasdaq
16.810,34
+124,37(+0,75%)
Nikkei 225
39.069,68
+282,30(+0,73%)
EUR/USD
1,0868
-0,0004(-0,03%)
Bitcoin EUR
62.690,95
+1.209,18(+1,97%)
CMC Crypto 200
1.380,54
+26,12(+1,93%)

NVCR Sep 2024 22.500 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

4,7100

+1,3600

(+40,60%)

In data: 09:48AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in